F Ossendorp
Overview
Explore the profile of F Ossendorp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1421
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kessler J, Beekman N, Bres-Vloemans S, Verdijk P, van Veelen P, Vissers D, et al.
J Exp Med
. 2001 Jan;
193(1):73-88.
PMID: 11136822
We report the efficient identification of four human histocompatibility leukocyte antigen (HLA)-A(*)0201-presented cytotoxic T lymphocyte (CTL) epitopes in the tumor-associated antigen PRAME using an improved "reverse immunology" strategy. Next to...
12.
van Bergen J, Camps M, Offringa R, Melief C, Ossendorp F, Koning F
Cancer Res
. 2000 Dec;
60(22):6427-33.
PMID: 11103809
Efficient loading of MHC class II molecules with a T helper epitope of choice can be achieved through genetic exchange of the MHC class II-associated invariant chain peptide (CLIP) sequence...
13.
Offringa R, van der Burg S, Ossendorp F, Toes R, Melief C
Curr Opin Immunol
. 2000 Sep;
12(5):576-82.
PMID: 11007362
After studies in preclinical mouse models, the efficacy and safety of tumor-specific vaccination strategies is currently being evaluated in cancer patients. The first wave of clinical trials has shown that...
14.
Ossendorp F, Toes R, Offringa R, van der Burg S, Melief C
Immunol Lett
. 2000 Sep;
74(1):75-9.
PMID: 10996631
No abstract available.
15.
van Hall T , Sijts A, Camps M, Offringa R, Melief C, Kloetzel P, et al.
J Exp Med
. 2000 Aug;
192(4):483-94.
PMID: 10952718
The proteasome is the principal provider of major histocompatibility complex (MHC) class I-presented peptides. Interferon (IFN)-gamma induces expression of three catalytically active proteasome subunits (LMP2, LMP7, and MECL-1) and the...
16.
Schuurhuis D, Laban S, Toes R, Ricciardi-Castagnoli P, Kleijmeer M, van der Voort E, et al.
J Exp Med
. 2000 Jul;
192(1):145-50.
PMID: 10880536
The well defined, immature murine dendritic cell (DC) line D1 was used to study the role of DC maturation in CTL induction in vitro and in vivo. Maturation of D1...
17.
Melief C, Toes R, Medema J, van der Burg S, Ossendorp F, Offringa R
Adv Immunol
. 2000 Jul;
75:235-82.
PMID: 10879286
No abstract available.
18.
van Hall T, van Bergen J, van Veelen P, Kraakman M, Heukamp L, Koning F, et al.
J Immunol
. 2000 Jul;
165(2):869-77.
PMID: 10878361
C57BL/6 mice generate a vigorous H-2Db-restricted CTL response against murine leukemia virus (MuLV)-induced tumors. For many years it has been suggested that this response is directed to an MuLV-encoded peptide...
19.
Beekman N, van Veelen P, van Hall T, Neisig A, Sijts A, Camps M, et al.
J Immunol
. 2000 Feb;
164(4):1898-905.
PMID: 10657639
CTL directed against the Moloney murine leukemia virus (MuLV) epitope SSWDFITV recognize Moloney MuLV-induced tumor cells, but do not recognize cells transformed by the closely related Friend MuLV. The potential...
20.
van Bergen J, Ossendorp F, Jordens R, Mommaas A, Drijfhout J, Koning F
Immunol Rev
. 2000 Jan;
172:87-96.
PMID: 10631939
The activation of MHC class II-restricted helper T cells is paramount to adaptive immune responses. Vaccine development could therefore benefit from improved ways of targeting antigens into MHC class II...